What we learnt from CSL, Challenger, Seek and Breville’s results
Investors in CSL and Breville have growth questions on their mind, while Seek’s downgrade sent shares skidding. Meanwhile, at Challenger, a bro-mance is brewing.
On the big days of this month’s earnings season, The Australian Financial Review’s Chanticleer columnists James Thomson and Anthony Macdonald extract the gold from the key profit results.
JT: Paul McKenzie hasn’t had the easiest start to his tenure as CSL chief executive. A few months in, he had to announce a rare profit downgrade, due to a drop in margins in the group’s flagship Behring business, which turns blood collected from donors into treatments for immunodeficiency and bleeding disorders.
Loading...
James Thomson is senior Chanticleer columnist based in Melbourne. He was the Companies editor and editor of BRW Magazine. Connect with James on Twitter. Email James at j.thomson@afr.com
Anthony Macdonald is a Chanticleer columnist. He is a former Street Talk co-editor and has 10 years' experience as a business journalist and worked at PwC, auditing and advising financial services companies. Connect with Anthony on Twitter. Email Anthony at a.macdonald@afr.com
